<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05126550</url>
  </required_header>
  <id_info>
    <org_study_id>Sinopharm21</org_study_id>
    <nct_id>NCT05126550</nct_id>
  </id_info>
  <brief_title>The Immunogenicity, Safety, and Effectiveness of the COVID-19 Inactivated Vaccine</brief_title>
  <official_title>The Immunogenicity, Safety, and Effectiveness of the SARS-CoV-2 Vaccine (Vero Cell) Inactivated in Adult Population Aged 18 Years Old and Above in Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Kimia Farma (Persero) Tbk</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT. Kimia Farma (Persero) Tbk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To fast respond the coronavirus disease of 2019 (COVID-19) pandemic, the Indonesian&#xD;
      government has launched &quot;Vaksinasi Gotong Royong&quot; (a mutual cooperation vaccination program)&#xD;
      in which any company/legal entity/business entity may purchase vaccines to be given free of&#xD;
      charge to their employees and families of employees (The Indonesian Ministry of Health,&#xD;
      2021). Vaccines provided for this program include the severe acute respiratory syndrome&#xD;
      coronavirus 2 (SARS-CoV-2) inactivated vaccines produced by Sinopharm.&#xD;
&#xD;
      The Indonesian National Agency of Drug and Food Control (NADFC) has issued an Emergency Use&#xD;
      Authorization (EUA) for several COVID-19 vaccines, including the SARS-CoV-2 vaccine (Vero&#xD;
      cell) inactivated produced by Sinopharm (NADFC, 2021). Following EUA, Kimia Farma Indonesia&#xD;
      as the holder of EUA has the obligation to monitor the safety and effectiveness in Indonesian&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 13, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of seropositivity of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>At 14 days, 3 months, and 6 months after 2 doses of vaccination</time_frame>
    <description>To evaluate the proportion of seropositivity of anti-SARS-CoV-2 neutralizing antibody following the SARS-CoV-2 vaccine (Vero cell) inactivated administration at 14 days, 3 months, and 6 months after 2 doses of vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The geometric mean titer (GMT) of anti-spike protein receptor binding domain (sRBD) immunoglobulin G (IgG) antibody and the proportion of seropositivity of anti-nucleocapsid antibody</measure>
    <time_frame>At 14 days, 3 months, and 6 months after 2 doses of vaccination</time_frame>
    <description>To evaluate the GMT of anti-sRBD IgG antibody and the proportion of seropositivity of anti-nucleocapsid antibody following the SARS-CoV-2 vaccine (Vero cell) inactivated administration at 14 days, 3 months, and 6 months after 2 doses of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of adverse event following immunization</measure>
    <time_frame>Within 28 days after 2 doses of vaccination</time_frame>
    <description>To evaluate the proportion of adverse event following immunization (AEFI) following the SARS-CoV-2 vaccine (Vero cell) inactivated administration after the first dose until 28 days after the second dose of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of serious adverse event</measure>
    <time_frame>Within 6 months after 2 doses of vaccination</time_frame>
    <description>To evaluate the proportion of serious adverse event following the SARS-CoV-2 vaccine (Vero cell) inactivated administration after the first dose until 6 months after the second dose of vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of symptomatic and PCR-confirmed SARS-CoV-2 infection</measure>
    <time_frame>Within 6 months after 2 doses of vaccination</time_frame>
    <description>To evaluate the proportion of symptomatic and PCR-confirmed SARS-CoV-2 infection following the SARS-CoV-2 vaccine (Vero cell) inactivated administration within 6 months after second dose of vaccination</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Immunogenicity</arm_group_label>
    <description>First 500 participants will be assigned to group 1 that constitute the immunogenicity group which will be evaluated regarding immunogenicity, safety, and effectiveness of the SARS-CoV-2 vaccine (Vero cell) inactivated produced by Sinopharm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Immunogenicity</arm_group_label>
    <description>The next 500 participants will be assigned to group 2 that constitute the non-immunogenicity group which will be evaluated regarding only safety and effectiveness of the aforementioned vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SARS-CoV-2 vaccine (Vero cell) inactivated</intervention_name>
    <description>Two doses of 0.5 mL intramuscular injection containing 4 mcg (6.5 Unit) antigens with an interval of 21-28 days in accordance with &quot;Vaksinasi Gotong Royong&quot; (mutual cooperation vaccination program)</description>
    <arm_group_label>Immunogenicity</arm_group_label>
    <arm_group_label>Non-Immunogenicity</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The recruitment will target potential participants via local company/legal entity/business&#xD;
        entity registering for &quot;Vaksinasi Gotong Royong&quot;&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Male or female subjects aged 18 years old and above Will receive the SARS-CoV-2 vaccine&#xD;
        (Vero cell) inactivated produced by Sinopharm Obtain informed consent to participate this&#xD;
        study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Previous SARS-CoV-2 vaccination History of SARS-CoV-2 infection&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prenali Dwisthi Sattwika, MD</last_name>
    <phone>+6281227167151</phone>
    <email>pdsattwika@ugm.ac.id</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jarir At Thobari, MD, PhD</last_name>
    <phone>+6282134180900</phone>
    <email>pusatcebu.fkkmk@ugm.ac.id</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 12, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gadjah Mada University</investigator_affiliation>
    <investigator_full_name>Prenali Dwisthi Sattwika</investigator_full_name>
    <investigator_title>Principal Investigator, Internist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

